Showing 2191-2200 of 9327 results for "".
Connective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.A Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.Going Off-Label
https://practicaldermatology.com/conferences/noah-worcester/going-off-label/57063/Francisca Kartono, DO, discusses her presentation, “Practical Pearls: Off-Label Topical and Systemic Strategies that Work,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.Improving Care Options for CTCL
https://practicaldermatology.com/videos/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-socioeconomic-neighborhood-status-linked-with-hs-severity-plus-more/39881/This episode highlights new data linking neighborhood socioeconomic status to hidradenitis suppurativa severity, as well as a new study of mitochondrial decline in skin cells leading to skin aging and even obesity. Also, a new Atopic Dermatitis Journal Club examines combination therapy with dupilumaA Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituNonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/videos/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/39781/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/videos/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fFirst Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/videos/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingThe Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.